<DOC>
	<DOCNO>NCT02109653</DOCNO>
	<brief_summary>This open-label , multi-center , single arm phase II study evaluate efficacy safety novel BRAF ( B-raf murine sarcoma viral oncogene homolog B1 ) inhibitor encorafenib ( LGX818 ) use single agent patient advance metastatic ( stage IIIB IV ) BRAF V600 mutant NSCLC . Patients must progress least one previous systemic , anti-cancer therapy locally advance metastatic NSCLC .</brief_summary>
	<brief_title>Efficacy Safety LGX818 Patients With Advanced Metastatic BRAF V600 Mutant NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Presence BRAF V600E mutation tumor tissue Histologically cytologically confirm diagnosis Stage IIIB IV NSCLC At least one measurable lesion define RECIST v1.1 Patients must progress least one previous systemic , anticancer treatment locally advance metastatic NSCLC . Eastern Cooperative Oncology Group ( ECOG ) /World Health Organization ( WHO ) performance status 02 Patients symptomatic Central Nervous System ( CNS ) metastases History leptomeningeal metastases Prior therapy BRAF inhibitor Patients take prohibited medication list protocol Presence history malignant disease NSCLC diagnose and/or require therapy within past 3 year . Impaired cardiovascular function clinically significant cardiovascular disease Pregnant lactate woman woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NSCLC ,</keyword>
	<keyword>Non-Small Cell Lung Cancer ,</keyword>
	<keyword>BRAF V600 ,</keyword>
	<keyword>LGX818</keyword>
</DOC>